Arbor Biotechnologies

Recent Finacing

Series B

Recent Raise

$215M

Arbor Biotechnologies develops precision genetic medicines via an AI/ML discovery platform and proprietary protein database to discover, screen and engineer CRISPR-based editors, enzymes, effectors for liver, CNS, ex vivo

Founded 2016

Massachusetts, United States

51-100

Private

arbor.bio

Highlights

Focus Areas

Biopharma

Biotechnology

Life Science

Recent Investors

P

Financials

$215M

Total Raised

1

Funding round

20

Investors

Team

Upgrade to view the team

See the team members at Arbor Biotechnologies.